Skip to main content
Genomma Lab Internacional, S.A.B. de C.V. logo

Genomma Lab Internacional, S.A.B. de C.V. — Investor Relations & Filings

Ticker · LAB ISIN · MX01LA010006 LEI · 984500B7084AA76ACF85 MX Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2026-05-07 AGM Information
Country MX Mexico
Listing MX LAB

About Genomma Lab Internacional, S.A.B. de C.V.

https://www.genommalab.com/

Genomma Lab Internacional, S.A.B. de C.V. specializes in the development, marketing, and distribution of over-the-counter (OTC) medications and personal care products. Established in 1996, the organization operates with a business model that combines pharmaceutical research with mass-market commercialization strategies. Its diverse portfolio encompasses various therapeutic categories and cosmetic segments, featuring recognized brands such as Cicatricure, Asepxia, Goicoechea, Tio Nacho, and XL-3. The company focuses on providing accessible health and wellness solutions through an extensive distribution network that reaches multiple international markets. By leveraging data-driven marketing and a robust supply chain, the entity aims to improve consumer well-being while maintaining a competitive presence in its active markets.

Recent filings

Filing Released Lang Actions
Acta de Asamblea Anual Ordinaria 29.04.26
AGM Information Classification · 95% confidence The document is a certified copy of the minutes of the Annual General Meeting (AGM) of Genomma Lab Internacional, S.A.B. de C.V. held on April 29, 2026. It includes detailed descriptions of the meeting proceedings, including presentation and approval of annual audited financial statements for the fiscal year ended December 31, 2025, dividend declarations, ratification of board actions, and other shareholder resolutions. The document is lengthy (15,000 characters) and contains the actual text of the meeting minutes, not just an announcement or summary. The content aligns with materials typically shared and approved during an AGM, including financial reports and corporate governance matters. Therefore, the document fits the category of AGM Information (AGM-R) rather than the Annual Report (10-K) or other categories. It is not a report publication announcement or a certification letter alone, but the full minutes of the AGM.
2026-05-07 Spanish
Opinión del Consejo de Admón. respecto del Informe del Direc
Annual Report Classification · 95% confidence The document is a detailed report addressed to the shareholders' meeting of Genomma Lab Internacional, S.A.B. de C.V., covering the fiscal year ended December 31, 2025. It includes the opinion of the Audit and Corporate Practices Committee on the CEO's report, the review and recommendation of the audited financial statements, and a comprehensive summary of the activities and decisions of the Board of Directors during the fiscal year. It also details dividend payments, auditor ratifications, and governance matters such as board composition. The document references the audited financial statements as an annex but contains substantive content about the financial results, governance, and management activities for the year. This aligns with the characteristics of an Annual Report (10-K), which covers company activity and full financial performance for the year. The length (15,000 characters) and depth of content confirm it is the report itself, not merely an announcement or certification. Therefore, the appropriate classification is Annual Report (10-K).
2026-05-05 Spanish
informe del Comité de Prácticas Societarias
Audit Report / Information Classification · 95% confidence The document is titled 'Informe del Comité de Auditoría y Prácticas Societarias' (Audit and Corporate Practices Committee Report) and is addressed to the Board of Directors and Shareholders Assembly of Genomma Lab Internacional, S.A.B. de C.V. It references the fiscal year ended December 31, 2025, and discusses audit activities, internal controls, external auditor evaluation, financial statement reviews, and corporate practices. The content is detailed and comprehensive, covering audit results, internal control assessments, auditor independence, and corporate governance practices. It is not a full annual report but a standalone audit committee report focusing on audit and corporate practices matters. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related information excluding full annual reports. The document length (12,998 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2026-05-05 Spanish
Informe del Consejo de Administración respecto de las Políti
Annual Report Classification · 95% confidence The document is a detailed report addressed to the shareholders' assembly of Genomma Lab Internacional, S.A.B. de C.V., covering the fiscal year ended December 31, 2025. It includes the opinion of the Audit and Corporate Practices Committee on the General Director's report, review and recommendation of the audited financial statements, discussion of accounting policies, and detailed activities of the Board of Directors during the fiscal year. It also includes information on dividends, auditor ratification, and board composition. The content is comprehensive and includes financial data, audit opinions, and management and board reports related to the annual fiscal year. This matches the characteristics of an Annual Report (10-K) rather than just an announcement or a summary. The document length (15,000 characters) and detailed content confirm it is the report itself, not a publication announcement or certification. Therefore, the correct classification is Annual Report (10-K).
2026-05-05 Spanish
Informe del Director General
Annual Report Classification · 95% confidence The document is a detailed report from the General Director to the Board of Directors and the Annual General Meeting of Shareholders of Genomma Lab Internacional, covering the fiscal year ended December 31, 2025. It includes a comprehensive discussion of the company's operational performance, financial results, and strategic outlook. The text references audited consolidated financial statements and the independent auditor's report for the years 2023, 2024, and 2025, which are included as annexes. The presence of full financial statements, auditor's opinion, and management discussion indicates this is a full annual report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K).
2026-05-05 Spanish
Informe del Comité de Auditoría
Audit Report / Information Classification · 95% confidence The document is titled 'Informe del Comité de Auditoría y Prácticas Societarias' (Audit and Corporate Practices Committee Report) and is addressed to the Board of Directors and Shareholders Assembly of Genomma Lab Internacional, S.A.B. de C.V. It references the fiscal year ended December 31, 2025, and discusses audit activities, internal controls, external auditor evaluation, financial statement reviews, and corporate governance practices. The document is detailed and contains substantive information about audit results, internal controls, and committee activities, consistent with an Audit Report or Information document. It is not a full Annual Report (10-K) as it focuses specifically on audit and corporate practices committee matters rather than comprehensive company financials and operations. It is not a short announcement or certification but a full committee report. Therefore, the appropriate classification is Audit Report / Information (AR).
2026-05-05 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.